secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001140361-23-043687
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma reaches FDA alignment on Phase 2 pivotal trial for RP-A501 in Danon Disease
--------------------------------------------------------------------------------

- FDA agreed to single-arm, open-label trial with 12 patients, natural history comparator, and co-primary endpoint of LAMP2 expression and LV mass at 12 months for accelerated approval.
- In-house cGMP manufacturing completed with sufficient drug product to supply the pivotal study; potency assays qualified per FDA guidance.
- ICD-10 code secured from CMS for LAMP2 deficiency; CTA/IMPD filing for EU initiation expected by end of Q3 2023.
- RP-A501 is a one-time infusion targeting a uniformly fatal cardiomyopathy with no approved therapies; affects 15,000–30,000 in US and Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036123043687/0001140361-23-043687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036123043687/ny20010507x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-043687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer